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ABSTRACT
Outcomes with conventional allogeneic hematopoietic cell transplantation (HCT) after failed HCT are
typically poor. To reduce transplantation-related mortality (TRM), 55 patients (median age, 43 years; range,
18-69 years) who had failed conventional autologous (n  49), allogeneic (n  4), or syngeneic (n  2) HCT
received human leukocyte antigen–matched related (n  31) or unrelated (n  24) donor allografts after
nonmyeloablative conditioning with 2 Gy of total body irradiation or 2 Gy of total body irradiation and 90
mg/m2 of fludarabine. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil.
One rejection occurred. Thirty-three patients died a median of 127 days (range, 7-834 days) after HCT: 21 of
relapse, 11 of TRM, and 1 of suicide. The TRM rate on day 100 was 11% with an estimated 1-year TRM rate
of 20% (95% confidence interval [CI], 9% to 31%). The median follow-up among the 22 survivors is 368 days
(range, 173-796 days). Seventeen of 22 survivors are progression-free. One-year estimates of overall and
progression-free survival rates are 49% (95% CI, 35% to 62%) and 28% (95% CI, 16% to 41%), respectively.
Untreated disease at the time of allografting after nonmyeloablative conditioning increased the risk of death
(hazard ratio  2.4; P  .04). Although the length of follow-up is still short, it appears that encouraging
outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with
conventional allografting.
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INTRODUCTION
For patients with hematologic malignancies who
fail conventional allogeneic or autologous hematopoi-
etic cell transplantations (HCT) because of relapse,
rejection, or development of new secondary malignan-
cies, options are limited. Patients with previous allo-
grafts may receive donor lymphocyte infusions (DLI)
or second allogeneic HCT. Patients with previous
autografts are often considered for salvage allogeneic
HCT. Whereas DLI can induce durable remissions in
patients with relapsed chronic myelogenous leukemia,
its efﬁcacy in treating other hematologic malignancies
in relapse after transplantation is less impressive [1,2].
Hence, salvage allografting is the only option with
curative intent for many patients. Unfortunately, out-
comes with conventional allografting after failed au-
tologous or allogeneic HCT are typically poor owing
to high transplantation-related mortality (TRM)
[3-9].
Recently, efforts have been made to decrease
TRM with reduced-intensity conditioning regimens
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that rely speciﬁcally on graft-versus-tumor effects to
eradicate malignancy [10-18]. A nonmyeloablative
regimen using low-dose total body irradiation (TBI)
with or without ﬂudarabine and postgrafting immu-
nosuppression with cyclosporine (CSP) and mycophe-
nolate mofetil (MMF) has shown feasibility and efﬁ-
cacy for patients with human leukocyte antigen
(HLA)–matched related and unrelated donors who
were considered ineligible for high-dose HCT based
on age or medical inﬁrmity [19-22]. This report de-
scribes outcomes for 55 patients with hematologic
malignancies who received allografts after nonmyelo-
ablative conditioning after having failed treatment
with conventional HCT, mostly autologous.
MATERIALS AND METHODS
Patient Characteristics and Eligibility
Between January 1999 and July 2001, 55 patients
(median age, 43 years; range, 18-69 years) underwent
allografting after nonmyeloablative conditioning after
failing conventional HCT. Patient diagnoses and his-
tories of previous HCTs are listed in Table 1. Patients
with non-Hodgkin’s lymphoma (NHL) were catego-
rized as having aggressive disease, based on interme-
diate- or high-grade histology, or indolent disease,
based on low-grade histology. Treatment centers in-
cluded the Fred Hutchinson Cancer Research Center,
University of Washington Medical Center, VA Puget
Sound Health Care System, University of Leipzig
(Germany), University of Colorado, Stanford Univer-
sity, City of Hope National Medical Center, Baylor
University, and University of Utah. HLA matching
included serological analysis for HLA-A, -B, and -C
and allele level typing for HLA-DRB1 and DQB1.
Eligibility requirements included the following: (1)
creatinine clearance level 50 mL/min, (2) total bili-
rubin level 2 times normal, and (3) Karnofsky per-
formance score 50. All patients were considered
ineligible for conventional allografts because of age
(older than 30 years), medical inﬁrmity, or high risk of
transplantation-related death. High risk was assumed
to be present in those patients whose previous condi-
tioning regimens had included high doses of TBI or
who had otherwise dose-limiting local irradiation, eg,
patients with NHL or Hodgkin’s disease (HD).
Patients had either previous autologous (n  49),
allogeneic (n  4), or syngeneic (n  2) HCT (Table
1). Five patients had more than 1 previous HCT.
Forty-six patients underwent allografting after non-
myeloablative conditioning for relapsed disease, 6 for
new secondary malignancies, 2 for both relapse and
new secondary malignancies, and 1 for autologous
graft failure. Twelve patients had disease that had
remained untreated after having failed conventional
HCT. Thirty patients had treatment-responsive dis-
ease and 13 had treatment-refractory disease at the
time of nonmyeloablative conditioning. All 9 patients
with myelodysplastic syndrome (MDS) (refractory
anemia  3, refractory anemia with excess blasts in
transformation  3, acute myeloid leukemia inductin
failure  1, agnogenic myeloid metaplasia  1, and
acute myelogenous leukemia (AML)  1) had evi-
dence of disease at HCT. Seven of the 9 patients with
MDS had secondary MDS that had developed after
high-dose autologous HCT for NHL (n  3), fallo-
pian tube carcinoma (n  1), AML (n  1), breast
cancer (n  1), or multiple myeloma (MM) (n  1).
The 8 patients with MM had either partial remissions
(PRs) (n  6) or were in relapse (n  2). The 15
patients with HD had either refractory disease (n 2),
were in relapse (n  4), had PR (n  7), or were in
complete remission (CR) (n  2). The 17 patients
with NHL had either refractory disease (n  3), were
in relapse (n 9), had PR (n 1), or were in CR (n
4). The 3 patients with chronic myeloid leukemia had
evidence of disease at transplantation; 1 patient was in
chronic phase, 1 in accelerated phase, and 1 in blast
crisis. One patient with acute lymphocytic leukemia
was in second CR and 1 was in fourth CR. The patient
with AML was in fourth CR. The 3 patients with
chronic myeloid leukemia were originally Philadel-
phia chromosome–positive. Additional cytogenetic
studies were available at the time of HCT in 24 of the
remaining 52 patients. Seven of the 24 (MDS  5,
MM  2) had complex chromosomal abnormalities.
The median duration from the time of conventional
HCT to nonmyeloablative conditioning was 22
months (range, 2-128 months).
Treatment and Evaluation
The ﬁrst 7 patients with HLA-matched related
donors were conditioned with 2 Gy of TBI given at 7
cGy/min from dual cobalt-60 sources or linear accel-
erators on day 0. To reduce the risk of rejection,
ﬂudarabine, 30 mg/m2 per day on days 4 to 2, was
Table 1. Patient Diagnoses
Disease
Previous HCT (No. of Patients)
Overall 1 Auto 2 Auto 3 Auto 1 Allo 2 Allo 1 Syn
NHL-A 16* 15 1 — — — —
NHL-I 3 3 — — — —
HD 15 14 — — — — 1
MM 8 5 2 1 — — —
MDS 7 7 — — — — —
CML 3 — — — 2 1 —
AL 3 1 — — 1 — 1
AL indicates acute leukemia; Allo, allogeneic transplantation;
Auto, autologous transplantation; NHL, A-Non Hodgkin’s lym-
phoma-Aggressive; NHL-I, non-Hodgkin’s lymphoma-Indolent;
Syn, Syngeneic transplant.
*Two patients with relapsed NHL also had secondary MDS.
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added to the preparative regimen for the subsequent
24 patients [20]. Granulocyte colony-stimulating fac-
tor–mobilized peripheral blood mononuclear cells (G-
PBMC) were infused on day 0. The median CD34
and CD3 cell counts among G-PBMC recipients
with HLA-matched related donors were 8.6 (range,
2.5-42.6)  106 cells/kg and 3.7 (range, 2.1-68.0) 
108 cells/kg, respectively. Postgrafting immunosup-
pression for patients with related donors included
CSP, 6.25 mg/kg orally twice daily on days -3 to 35,
then tapered to day 56, and MMF, 15 mg/kg twice
daily on days 0 to 27.
Patients with HLA-matched unrelated donors all
received ﬂudarabine, 30 mg/m2 per day on days 4 to
2, and 2 Gy of TBI on day 0. Among patients with
unrelated donors, 6 received marrow and 18 received
G-PBMC as the stem cell sources. The median
CD34 and CD3 cell counts were 8.7 (range, 3.6-
28.1)  106 cells/kg and 3.0 (range, 1.0-5.0)  108
cells/kg, respectively. The median CD34 and CD3
cell numbers infused with the marrow were 2.3 (range,
1.9-2.8)  106 cells/kg and 0.2 (range, 0.2-0.5)  108
cells/kg, respectively. As a means of dealing with the
theoretical increased incidence of graft-versus-host
disease (GVHD) compared with the HLA-matched
related recipients, postgrafting immunosuppression
was extended, and patients with unrelated donors re-
ceived CSP, 6.25 mg/kg orally twice daily on days 3
to 100, then tapered off by day 180, and MMF, 15
mg/kg twice daily on days 0 to 40, then tapered off
by day 96. CSP levels were targeted to the upper
therapeutic range (approximately 500 ng/mL; Abbott
TDX, Abbott Park, IL) until day 28.
The degrees of donor chimerism among periph-
eral blood T cells, granulocytes, and unfractionated
marrow were assessed at days 28, 56, and 84
after transplantation using ﬂuorescence in situ hybrid-
ization analyses for recipients of sex-mismatched
transplants [23] and polymerase chain reaction–based
analyses of variable number tandem repeats for recip-
ients of sex-matched transplants [24].
Acute and chronic GVHD were graded as de-
scribed [25]. Prophylactic therapies against Pneumocys-
tis carinii, Candida infections, herpes simplex virus, and
cytomegalovirus were administered as described [26-29].
Tumor responses were assessed using standard
criteria. Patients were eligible for DLI if their immu-
nosuppression was discontinued, they were without
evidence of acute or clinical extensive chronic GVHD,
and they had persistence or progression of the under-
lying disease. The ﬁrst DLI included a dose of 1 107
CD3 cells/kg; the second (if indicated) a dose of
3.2  107 CD3 cells/kg. Seven patients, all with
HLA-identical related donors, received 1 or 2 DLI for
relapsed or progressive disease.
Statistical Analysis
Overall survival (OS) and progression-free sur-
vival (PFS) were estimated using the Kaplan-Meier
method, and TRM and relapse-related mortality were
summarized using cumulative incidence estimates
[30]. Relapse or disease progression was regarded as a
competing risk for TRM, and death without relapse or
progression was regarded as a competing risk for re-
lapse-related mortality. Cox regression models were
used to examine the association of various clinical risk
factors with the hazard of failure from death or pro-
gression [31]. Factors examined included the follow-
ing: type of donor (HLA-matched related versus un-
related), age at nonmyeloablative HCT (analyzed as a
continuous variable), time from most recent conven-
tional HCT to allografting after nonmyeloablative
conditioning, previous TBI, previous chest irradia-
tion, stages of diseases at the time of nonmyeloablative
HCT (untreated, treatment sensitive, or treatment
refractory), and diagnoses (HD, NHL-aggressive,
MM, and other). Acute and chronic GVHD were
considered as time-dependent covariates in regression
models for relapse or progression and mortality. The
statistical signiﬁcance of the correlation between risk
factors was examined using the chi-square test if each
factor was categorical or the Wilcoxon rank-sum test
if one of the factors was continuous. Two-sided P
values resulting from the regression models were de-
rived from the Wald test, and no adjustments were
made for multiple comparisons. Data as of March 1,
2002, were subsequently analyzed.
RESULTS
Engraftment
Complete chimerism data were available for 46
patients. Median percentages of donor chimerism of
the peripheral blood T compartment are shown in
Figure 1. Median donor T-cell chimerism among 46 patients given
nonmyeloablative conditioning before allogeneic HCT.
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Figure 1. Full donor engraftment was rapid. One
patient with refractory secondary AML rejected the
unrelated donor marrow graft (2.0  106 CD34/kg)
33 days after HCT and died of relapse on day 77.
The remaining 45 patients for whom chimerism data
were available all had sustained engraftment.
The median number of days with absolute neutro-
phil counts (ANC) 500/L was 1 (range, 0-41), and
24 patients maintained ANCs 500/L after HCT.
The median ANC nadir was 455 (range, 0-1720)/L.
The median platelet nadir was 37,000 (range,
0-177,000)/L, and the median number of days with
platelet counts 20,000/L was 0 (range, 0-41).
Thirty-one patients (58%) required no platelet
transfusions. Among the remaining 24 patients, a me-
dian of 0 (range, 0-213) platelet units were transfused.
Seventeen patients (32%) required no red blood cell
transfusions, whereas 38 patients received a median of
2 (range, 0-22) red blood cell units.
Toxicities
Patients at the University of Leipzig (n  3) had
scheduled hospital admissions for HCT. Data regard-
ing hospitalization were available for 51 of the 52
remaining patients who were eligible for outpatient
transplantation. Eleven (22%) did not require hospi-
talization within the ﬁrst 60 days after HCT. The
remainder were hospitalized for a median of 8 days
(range, 1-60 days).
The incidence of grades II, III, and IV acute
GVHD for the 31 patients with HLA-matched related
donors was 29%, 13%, and 6%, respectively. Among
21 patients with related donors and greater than 100
days of follow-up, 14 (67%) required extended immu-
nosuppressive treatment for chronic GVHD. The in-
cidence of grades II, III, and IV acute GVHD for the
24 patients with HLA-matched unrelated donors was
38%, 8%, and 4%, respectively. Among 18 patients
with unrelated donors followed up for more than 100
days, 10 (56%) required treatment for chronic
GVHD.
TRM rate at day 100 was 11% with an estimated
1-year TRM rate of 20% (95% conﬁdence interval
[CI], 9%-31%). Causes of death included GVHD
(n  5), infection (n  7), and multiorgan failure (n 
9), with 7 of 11 patients having more than 1 cause of
death. A death due to suicide occurred but was not
considered transplantation related.
Results of univariate Cox regression models for
TRM are described in Table 2. Previous TBI (hazard
ratio [HR] 3.3; P  .08) and untreated disease (HR
2.4; P .18) were associated with increased hazards of
TRM, whereas having an unrelated donor (HR 0.3;
P  .08) conferred a decreased hazard of TRM, al-
though none of these associations reached statistical
signiﬁcance.
Donor Lymphocyte Infusions
Seven patients received 1 to 2 DLIs for relapsed or
progressive disease. All 7 had received HLA-matched
related donor grafts. The diagnoses of the patients
receiving DLI were HD (n  3), MM (n  3), and
NHL, aggressive subtype (n  1). One patient re-
mained alive with disease progression with follow-up
of 735 days. Five relapse-related deaths and 1 trans-
plantation-related death have occurred after DLI.
Relapse and Survival
Overall, the relapse mortality rate at day 100 was
13% with an estimated 1-year relapse-related mortal-
ity rate of 31% (95% CI, 17%-44%). With a median
follow-up of 368 days (range, 173-796 days) among all
survivors, the estimated OS and PFS rates at 1 year
were 49% (95% CI, 35%-62%) and 28% (95% CI,
16%-41%), respectively (Figure 2).
Results of univariate Cox regression models for
overall mortality and PFS are described in Table 3 and
Table 4. Untreated disease at the time of allografting
after nonmyeloablative conditioning (HR 2.4; P 
.04) and previous TBI (HR 2.2; P  .11) were asso-
ciated with suggestively increased hazards of overall
mortality, whereas untreated disease suggested an in-
creased hazard of disease progression (HR 2.1; P .06).
Table 2. Results of Univariate Cox Regression Models for TRM
Factor HR 95% CI P
Donor type
MRD 1 — —
URD 0.3 0.1-1.2 .08
Age* 0.8 0.5-1.3 .42
Time to NMT† 1.1 0.9-1.3 .53
Prior TBI
No 1 — —
Yes 3.3 0.9-12.4 .08
Prior Chest XRT
No 1 — —
Yes 0.8 0.2-3.8 .80
Disease stage
Sensitive 1 — —
Refractory 0.8 0.2-4.1 .82
Untreated 2.4 0.7-8.7 .18
Diagnosis
Others 1 — —
HD 1.6 0.4-6.7 .52
NHL-A 1.0 0.2-4.8 .97
MM 0.5 0.1-5.3 .60
MRD indicates matched related donor; NHL-A, non-
Hodgkin’s lymphoma, aggressive subtype; NMT, nonmyeloablative
transplantation; URD, unrelated donor; XRT, radiation therapy.
*Modeled as a continuous variable, HR presented in terms of an
increase in age of 10 y.
†Modeled as a continuous variable, HR presented in terms of an
increase in time of 10 months.
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The Impact of GVHD on Relapse or Progression
and Mortality
The hazard of disease relapse or progression was
lower among patients with grades II to IV acute
GVHD compared with that among patients with
grades 0 to I GVHD; however, the difference was not
statistically signiﬁcant (HR  0.7; 95% CI, 0.3-1.6;
P  .36). Conversely, the hazard of mortality was
increased among patients with grades II to IV acute
GVHD (HR  1.5; 95% CI, 0.7-3.1; P  .27), al-
though this difference also was not statistically signif-
icant. Similarly, the hazard of relapse or progression
decreased among patients with chronic GVHD
(HR  0.8; 95% CI, 0.2-2.7; P  .70) compared with
those without chronic GVHD with an increased haz-
ard of mortality (HR 1.3; 95% CI, 0.5-3.8; P .61).
Excluding patients with grade IV GVHD (whose
transplantation-related death would preclude relapse
or progression) yielded similar results with a decreased
hazard of relapse (HR  0.8; 95% CI, 0.3-1.8; P 
.52) being offset by an increased hazard of mortality
(HR  1.3; 95% CI, 0.6-2.8; P  .52).
DISCUSSION
We retrospectively evaluated the results of 55 pa-
tients who received allografts after nonmyeloablative
conditioning from either related or unrelated HLA-
matched donors after failing conventional HCT. The
estimated probabilities of OS, PFS, and TRM 1 year
after nonmyeloablative conditioning and HCT were
49%, 28%, and 20%, respectively. Having untreated
disease at the time of HCT appeared to increase the
hazard of failure due to death or progression. Previous
TBI increased the hazard of TRM; however, the
power to detect a statistically signiﬁcant difference
was limited by the number of transplantation-related
deaths.
The low rejection rate observed among current
patients likely reﬂected effective immunosuppression
from both the transplantation regimen as well as the
previous treatment. The 1 patient who rejected his
graft had refractory secondary AML and received an
Figure 2. OS, PFS, and TRM for 54 patients who had failed
conventional HCT and were given HLA-matched related or unre-
lated donor allografts after nonmyeloablative conditioning.
Table 3. Results of Univariate Cox Regression Models
for Overall Mortality
Factor HR 95% CI P
Donor type
MRD 1 — —
URD 0.9 0.4-1.8 .74
Age* 1.0 0.8-1.4 .85
Time to NMT† 1.0 0.9-1.2 .68
Prior TBI
No 1 — —
Yes 2.2 0.8-5.9 .11
Prior chest XRT
No 1 — —
Yes 0.7 0.3-1.9 .51
Disease stage
Sensitive 1 — —
Refractory 1.1 0.4-2.6 .88
Untreated 2.4 1.1-5.3 .04
Diagnosis
Others 1 — —
HD 0.8 0.3-1.9 .56
NHL-A 0.7 0.3-1.7 .40
MM 0.7 0.3-2.0 .50
*Modeled as a continuous variable, HR presented in terms of an
increase in age of 10 years.
†Modeled as a continuous variable, HR presented in terms of an
increase in time of 10 months.
Table 4. Results of Univariate Cox Regression Models for PFS,
Where “Failure” is the First of Death or Disease Relapse/Progression
Factor HR 95% CI P
Donor type
MRD 1 — —
URD 0.8 0.4-1.5 .43
Age* 0.9 0.7-1.2 .46
Time to NMT† 1.0 0.9-1.1 .67
Prior TBI
No 1 — —
Yes 1.4 0.5-3.5 .52
Prior chest XRT
No 1 — —
Yes 0.9 0.4-2.1 .85
Disease stage
Sensitive 1 — —
Refractory 1.5 0.7-3.1 .33
Untreated 2.1 1.0-4.6 .06
Diagnosis
Others 1 — —
HD 1.3 0.5-2.9 .59
NHL-A 1.0 0.4-2.4 .97
MM 1.0 0.4-2.7 .98
*Modeled as a continuous variable, HR presented in terms of an
increase in age of 10 years.
†Modeled as a continuous variable, HR presented in terms of an
increase in time of 10 months.
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unrelated donor marrow infusion with a low CD34
cell dose. In a recent analysis of other patients with
unrelated donor allografts who received the current
nonmyeloablative regimen, the diagnosis of MDS and
receipt of marrow compared with G-PBMC as the
stem cell source conferred increased risks of rejec-
tion [21].
Among the 6 patients (all with unrelated donors)
who received marrow infusions, all experienced re-
lapse or progressive disease, and 5 have died of their
disease. The limited number of patients receiving
marrow precluded a more rigorous comparison of
marrow and G-PBMC as stem cell sources among
current patients who failed conventional HCT. How-
ever, a recent analysis of all patients, including those
with other malignancies and without previous au-
tografts, receiving unrelated donor allografts with this
regimen, showed that G-PBMC as the stem cell
source conferred not only superior engraftment, but
also better OS and PFS compared with marrow [21].
This is the largest reported series of allografting
after nonmyeloablative conditioning as salvage ther-
apy after failed high-dose conventional HCT. Nagler
et al. [32] evaluated 12 patients (median age, 33 years;
range, 8-63 years) who received allografts from HLA-
identical siblings for relapsed disease or secondary
malignancies after failed autologous HCT. Condi-
tioning consisted of ﬂudarabine, busulfan, and anti-
thymocyte globulin. One nonrelapse death occurred,
and 6 patients were free of disease with a median
follow-up of 23 months. Actuarial and disease-free
survival rates at 34 months were 56% and 50%, re-
spectively.
Dey et al. [33] described 13 patients (median age,
43 years; range, 24-62 years) who failed autologous
HCT and received HLA-matched related donor allo-
grafts after conditioning with cyclophosphamide and
antithymocyte globulin with or without thymic irra-
diation. Only 1 nonrelapse death occurred. Median
survival was 10 months (range, 3-39 months) with
2-year estimates of overall and disease-free survival
rates of 45% and 38%, respectively.
Devine et al. [34] studied 11 patients (median age,
41 years; range, 22-58 years) who relapsed after au-
tologous or allogeneic HCT and received second
transplants from HLA-identical or mismatched re-
lated donors after a ﬂudarabine-based regimen.
Whereas full donor engraftment was achieved in all
but 1 patient, 10 of 11 died a median of 140 days
(range, 9-996 days) after transplantation; 5 of relapse
and 5 of nonrelapse causes. Because only one of the
patients was in CR at the time of HCT, the authors
suggested that advanced disease at the time of al-
lografting after nonmyeloablative conditioning had a
negative impact on outcome.
Although length of follow-up is short, allografting
after nonmyeloablative conditioning appears to be a
feasible treatment option for patients who have failed
mostly autologous, conventional HCT. TRM with
this approach is low. Having untreated disease at the
time of allografting after nonmyeloablative condition-
ing or previous TBI may confer a worse outcome.
However, age, duration from conventional HCT, di-
agnoses, and type of donor did not appear to signiﬁ-
cantly inﬂuence overall mortality.
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